Discover how the 340B drug pricing program, intended to help low-income patients, has become a system of abuse and misuse ...

Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

Proposition 34 confronts the longtime abuse of the federal 340B prescription drug program and will hold bad actors ...

The federal 340B Drug Pricing Program — a noble idea first enacted in 1992 — needs to be brought back into the shop for ...

The 340B program's “covered entities” serve low-income, poorer populations that tend to be un- or underinsured. Many, if not ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

Minnesota releases a report on the 340B Drug Pricing Program, highlighting the need for transparency in healthcare economics.

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...